$147.41 +3.77 (%) Amgen Inc - NASDAQ

Oct. 23, 2014 | 01:00 PM

Partner Headlines

  1. Fast Money Picks For October 23

    Benzinga | Oct. 23, 2014 | 07:00AM EST
  2. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  3. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD | Oct. 22, 2014 | 17:01PM EST
  4. Daniel Loeb Comments on Amgen Inc

    GuruFocus | Oct. 22, 2014 | 12:06PM EST
  5. Third Point Q3 2014 Investor Letter

    GuruFocus | Oct. 22, 2014 | 10:24AM EST
  6. Markets In Rally Mode: S&P 500 And Nasdaq Surge As Dow Lags

    Benzinga | Oct. 21, 2014 | 16:41PM EST
  7. Third Point's Notable Additions And Exit: Alibaba, eBay, Sony

    Benzinga | Oct. 21, 2014 | 15:38PM EST
  8. Stocks To Watch For October 20, 2014

    Benzinga | Oct. 20, 2014 | 04:43AM EST
  9. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD | Oct. 18, 2014 | 08:02AM EST
  10. Regeneron's Eylea Tops Rivals

    IBD | Oct. 17, 2014 | 18:45PM EST
  11. Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors

    Benzinga | Oct. 17, 2014 | 16:20PM EST
  12. Regeneron Eye Drug Beats Rivals While Amgen Sues

    IBD | Oct. 17, 2014 | 11:27AM EST
  13. Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement

    Benzinga | Oct. 17, 2014 | 09:01AM EST
  14. Most Top Industry Groups Fall Harder Than Market

    IBD | Oct. 10, 2014 | 17:58PM EST
  15. UPDATE: Amgen's BiTE Received FDA Priority Review Designation

    Benzinga | Oct. 9, 2014 | 16:06PM EST
  16. Illumina Pads Gene Sequencing Lead With Pharma Deals

    IBD | Oct. 8, 2014 | 16:04PM EST
  17. Some Old Stocks Still Have Young Legs

    IBD | Oct. 6, 2014 | 18:47PM EST
  18. Amgen, Inc. Showing Strong Performance Despite Low Beta

    Benzinga | Sep. 30, 2014 | 12:06PM EST
  19. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD | Sep. 24, 2014 | 13:27PM EST
  20. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD | Sep. 22, 2014 | 19:05PM EST
  21. These 3 Biotech Stocks Just Hit New Highs

    Benzinga | Sep. 22, 2014 | 13:31PM EST
  22. Amgen Submits Biologics License Application For Investigational BiTE Immunotherapy Blinatumomab

    Benzinga | Sep. 22, 2014 | 09:02AM EST
  23. Amgen: Stronger Drug Portfolio with Acquisition

    GuruFocus | Sep. 22, 2014 | 03:12AM EST
  24. Insider Buys at Halozyme Look to Improve Stock Outlook

    GuruFocus | Sep. 18, 2014 | 17:49PM EST
  25. Amgen, Inc. Poised To Break Higher

    Benzinga | Sep. 17, 2014 | 14:34PM EST
  26. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. As Brodalumab Doesn't Need To Be Forgotten

    Benzinga | Sep. 17, 2014 | 09:50AM EST
  27. UPDATE: Morgan Stanley Reiterates On Amgen, Inc. Following Healthcare Conference

    Benzinga | Sep. 11, 2014 | 08:54AM EST
  28. Amgen, Inc. Showing More Upside Potential

    Benzinga | Sep. 10, 2014 | 16:06PM EST
  29. Why Gilead Sciences, Inc. Is A Top Mutual Fund Holding

    Benzinga | Sep. 5, 2014 | 09:27AM EST
  30. Novartis, Regeneron Cardio Results Pump Up Wall St.

    IBD | Sep. 2, 2014 | 18:04PM EST
  31. Novartis, Regeneron Hit New Highs On Cardio Drugs

    IBD | Sep. 2, 2014 | 11:19AM EST
  32. Amgen edges up on trial results

    IBD | Aug. 28, 2014 | 18:42PM EST
  33. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 28, 2014 | 10:19AM EST
  34. Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)

    Benzinga | Aug. 27, 2014 | 15:22PM EST
  35. After Reaching All-Time Highs, How Can Gilead Sciences Continue growing?

    GuruFocus | Aug. 27, 2014 | 15:06PM EST
  36. HCP Boosts Of 29 Years Of Dividend Increases

    IBD | Aug. 26, 2014 | 17:27PM EST
  37. The Tech Industry is Vanishing Before Our Eyes

    FoxBusiness | Aug. 21, 2014 | 13:44PM EST
  38. Stocks End With Small Gains; Amgen Shrugs Off Drug Data

    IBD | Aug. 14, 2014 | 16:25PM EST
  39. AMGEN

    IBD | Aug. 13, 2014 | 18:58PM EST
  40. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga | Aug. 7, 2014 | 04:24AM EST
  41. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD | Aug. 5, 2014 | 18:30PM EST
  42. Cancer 'Cocktail' Passes Test

    IBD | Aug. 4, 2014 | 18:41PM EST
  43. Nasdaq Leads In Quiet Session; Priceline Nears Buy Point

    IBD | Aug. 4, 2014 | 14:53PM EST
  44. Amgen Cancer Drug Kyprolis Succeeds In Trial

    IBD | Aug. 4, 2014 | 10:56AM EST
  45. Morning Market Movers

    Benzinga | Aug. 4, 2014 | 09:41AM EST
  46. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 4, 2014 | 08:05AM EST
  47. UPDATE: Amgen Announces Phase 3 ASPIRE Trial of Kyprolis Met Primary Endpoint, Helped Patients Live Longer without Worsening

    Benzinga | Aug. 4, 2014 | 07:34AM EST
  48. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga | Jul. 30, 2014 | 16:43PM EST
  49. Amgen Price Target Raised by Various Analysts

    Benzinga | Jul. 30, 2014 | 13:42PM EST
  50. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD | Jul. 30, 2014 | 11:20AM EST
Trading Center